Twist Bioscience's book value per share for the quarter that ended in Mar. 2024 was €8.86.
During the past 12 months, Twist Bioscience's average Book Value Per Share Growth Rate was -21.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Twist Bioscience was 44.50% per year. The lowest was 13.20% per year. And the median was 28.85% per year.
Twist Bioscience's current price is €42.61. Its book value per share for the quarter that ended in Mar. 2024 was €8.86. Hence, today's PB Ratio of Twist Bioscience is 4.81.
During the past 8 years, the highest P/B Ratio of Twist Bioscience was 21.99. The lowest was 0.97. And the median was 4.85.
Twist Bioscience Book Value per Share Historical Data
The historical data trend for Twist Bioscience's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Twist Bioscience's Book Value per Share
For the Diagnostics & Research subindustry, Twist Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's PB Ratio falls into.
Twist Bioscience Book Value per Share Calculation
Twist Bioscience's Book Value Per Share for the fiscal year that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Twist Bioscience (FRA:0ME) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Twist Bioscience Book Value per Share Related Terms
Thank you for viewing the detailed overview of Twist Bioscience's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:0ME has been successfully added to your 